Search research articles
Contact Us
Filters
Showing results (281-290 of 294) with videos related to
Page
of 30
Sort By:
Chemical Society Reviews
|
May 2, 2020
QSAR without borders
Eugene N Muratov, Jürgen Bajorath, Robert P Sheridan, et al.
Experimental Hematology
|
January 29, 1999
The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice
T R Ulich, J del Castillo, G Senaldi, et al.
Annals of Internal Medicine
|
October 1, 1994
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial
D W Maher, G J Lieschke, M Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2020
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Ravi Vij, Rajneesh Nath, Daniel E H Afar, et al.
Allergy
|
November 28, 2020
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial
Isao Ohsawa, Daisuke Honda, Yusuke Suzuki, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 2, 2021
Functional genomics and metabolomics advance the ethnobotany of the Samoan traditional medicine "matalafi"
Seeseei Molimau-Samasoni, Victoria Helen Woolner, Su'emalo Talie Foliga, et al.
Iscience
|
June 8, 2026
Multi-omics reveal phosphatidic acid phosphatases modify Niemann-Pick type C disease severity
Andrew B Munkacsi, Gabriella E Conway, Keri Multerer, et al.
Nature
|
March 5, 2014
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Travis K Warren, Jay Wells, Rekha G Panchal, et al.
Clinical and Translational Allergy
|
June 23, 2021
Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study
Henriette Farkas, Marcin Stobiecki, Jonny Peter, et al.
Allergy
|
April 25, 2018
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study
M A Riedl, E Aygören-Pürsün, J Baker, et al.
Page
of 30
Search research articles
Search
Showing results (281-290 of 294) with videos related to
Sort By:
Page
of 30
Chemical Society Reviews
|
May 2, 2020
QSAR without borders
Eugene N Muratov, Jürgen Bajorath, Robert P Sheridan, et al.
Experimental Hematology
|
January 29, 1999
The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice
T R Ulich, J del Castillo, G Senaldi, et al.
Annals of Internal Medicine
|
October 1, 1994
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial
D W Maher, G J Lieschke, M Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2020
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Ravi Vij, Rajneesh Nath, Daniel E H Afar, et al.
Allergy
|
November 28, 2020
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial
Isao Ohsawa, Daisuke Honda, Yusuke Suzuki, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 2, 2021
Functional genomics and metabolomics advance the ethnobotany of the Samoan traditional medicine "matalafi"
Seeseei Molimau-Samasoni, Victoria Helen Woolner, Su'emalo Talie Foliga, et al.
Iscience
|
June 8, 2026
Multi-omics reveal phosphatidic acid phosphatases modify Niemann-Pick type C disease severity
Andrew B Munkacsi, Gabriella E Conway, Keri Multerer, et al.
Nature
|
March 5, 2014
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Travis K Warren, Jay Wells, Rekha G Panchal, et al.
Clinical and Translational Allergy
|
June 23, 2021
Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study
Henriette Farkas, Marcin Stobiecki, Jonny Peter, et al.
Allergy
|
April 25, 2018
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study
M A Riedl, E Aygören-Pürsün, J Baker, et al.
Page
of 30